These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11707316)

  • 41. Effects of Ca2+ antagonists nifedipine and diltiazem on isolated human chorionic arteries and veins.
    Reviriego J; Fernandez-Alfonso MS; Guerra P; Marín J
    J Cardiovasc Pharmacol; 1990 Jul; 16(1):128-38. PubMed ID: 1696655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antihypertensive properties of ketanserin (R 41 468).
    Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA
    Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypotensive and antiaggregative effects of eugenosedin-B with serotonin and alpha/beta-adrenoceptor antagonistic activities in rats and human platelets.
    Shen KP; Chu LW; Hsieh SL; An LM; Chen IJ; Wu BN
    J Cardiovasc Pharmacol; 2008 Feb; 51(2):154-61. PubMed ID: 18287883
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diverse regulation of atrial natriuretic peptide secretion by serotonin receptor subtypes.
    Cao C; Han JH; Kim SZ; Cho KW; Kim SH
    Cardiovasc Res; 2003 Aug; 59(2):360-8. PubMed ID: 12909319
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ability of ketanserin to block different receptors in human placental vessels.
    Marin J; Reviriego J; Fernandez-Alfonso MS
    J Pharm Pharmacol; 1990 Mar; 42(3):217-20. PubMed ID: 1974625
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension.
    Hedner T; Persson B
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):317S-323S. PubMed ID: 3046635
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ketanserin causes surmountable antagonism of 5-hydroxytryptamine-induced contractions of large coronary arteries of dog.
    Frenken M; Kaumann AJ
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Jan; 328(3):301-3. PubMed ID: 3157065
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanism of the hypotensive effect of ketanserin.
    Fozard JR
    J Cardiovasc Pharmacol; 1982; 4(5):829-38. PubMed ID: 6182416
    [No Abstract]   [Full Text] [Related]  

  • 49. Haemodynamic response to ketanserin in rabbits with Page hypertension: comparison with prazosin.
    Wright CE; Angus JA
    J Hypertens; 1983 Aug; 1(2):183-90. PubMed ID: 6681038
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of antagonists of 5-hydroxytryptamine on blood pressure in the anesthetised spontaneously hypertensive rat.
    Docherty JR; Warnock P
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S59-61. PubMed ID: 2446073
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antagonistic actions of renal dopamine and 5-hydroxytryptamine: endogenous 5-hydroxytryptamine, 5-HT1A receptors and antinatriuresis during high sodium intake.
    Soares-da-Silva P; Vieira-Coelho MA; Pestana M
    Br J Pharmacol; 1996 Mar; 117(6):1193-8. PubMed ID: 8882615
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ketanserin-sensitive depressant actions of 5-HT receptor agonists in the neonatal rat spinal cord.
    Manuel NA; Wallis DI; Crick H
    Br J Pharmacol; 1995 Nov; 116(6):2647-54. PubMed ID: 8590984
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular effects of ketanserin in closed-chest anesthetized dogs.
    van de Water A; Wouters L; Xhonneux R; Reneman S
    Arch Int Pharmacodyn Ther; 1985 Jun; 275(2):267-78. PubMed ID: 3161481
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency.
    Wenting GJ; Woittiez AJ; Man in't Veld AJ; Schalekamp MA
    Hypertension; 1984; 6(1):100-9. PubMed ID: 6319278
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ketanserin potentiates the prejunctional inhibitory effect of 5-hydroxytryptamine on rat vas deferens.
    Moritoki H; Fukuda H; Kanaya J; Ishida Y
    J Pharm Pharmacol; 1986 Oct; 38(10):737-41. PubMed ID: 2878993
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ketanserin versus urapidil: age-related cardiovascular effects in conscious rats.
    Buñag RD; Thomas CV; Mellick JR
    Eur J Pharmacol; 2002 Jan; 435(1):85-92. PubMed ID: 11790382
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stimulatory effects of 5-hydroxytryptamine on fluid secretion and transmural potential difference in rat small intestine are mediated by different receptor subtypes.
    Beubler E; Coupar IM; Hardcastle J; Hardcastle PT
    J Pharm Pharmacol; 1990 Jan; 42(1):35-9. PubMed ID: 1969947
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serotonergic mechanisms and blood pressure in sheep.
    Nelson MA; Coghlan JP; Denton DA; Mills EH; Scoggins BA; Spence CD; Whitworth JA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S117-9. PubMed ID: 2412029
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.
    Van Nueten JM; Janssen PA; Van Beek J; Xhonneux R; Verbeuren TJ; Vanhoutte PM
    J Pharmacol Exp Ther; 1981 Jul; 218(1):217-30. PubMed ID: 6113280
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studies.
    Broderick PA; Olabisi OA; Rahni DN; Zhou Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):547-57. PubMed ID: 15093963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.